All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to Buy
Yahoo Finance · Oct 12, 2026 · Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
Contineum Therapeutics, Inc. (CTNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Not investment advice. Headline and summary only, not a full reprint.